Lawitz, E., Gane, E., Pearlman, B., Tam, E., Ghesquiere, W., Guyader, D., Alric, L., Bronowicki, J., Lester, L., Sievert, W., Ghalib, R., Balart, L., Sund, F., Lagging, M., Dutko, F., Shaughnessy, M., Hwang, P., Howe, A. Y. M., Wahl, J., Robertson, M., Barr, E., & Haber, B. (2015). efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet, 385(9973), 1075–1086. http://access.bl.uk/ark:/81055/vdc_100042507111.0x00004a